Novartis Reference: PAT051937-US-PCT

Mofo Reference: 223002100300

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mariagrazia PIZZA

Application No.: 10/530,753

Filing Date: (Intl.) October 2, 2003

For: POLYPEPTIDE-VACCINES FOR

BROAD PROTECTION AGAINST

HYPERVIRULENT MENINGOCOCCAL

LINEAGES

Examiner: B. J. Gangle

Group Art Unit: 1645

Confirmation No.: 7340

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & § 1.98

MAIL STOP: AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

Application No.: 10/530,753 2 Novartis Reference: PAT051937-US-PCT Mofo Reference: 223002100300

This Supplemental Information Disclosure Statement is submitted: With the application; accordingly, no fee or separate requirements are required.  $\boxtimes$ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided. П Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided. After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance. A fee is required. Accordingly, a Fee Transmittal Form (PTO/SB/17) is attached to this submission. A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due. After mailing of a final Office Action or Notice of Allowance, but before payment of the Issue Fee. A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal Form (PTO/SB/17) is attached to this submission.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Application No.: 10/530,753 3 Novartis Reference: PAT051937-US-PCT

Mofo Reference: 223002100300

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **Docket No. 223002100300**.

Dated: September 24, 2010 Respectfully submitted,

By /Otis Littlefield/
Otis B. Littlefield
Registration No.: 48,751

MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105-2482 Telephone: 415.268.6846

Fax: 415.268.7522